Skip to content
Calculator
Comparison

Retatrutide vs CagriSema vs tirzepatide: the next-generation scorecard

Last updated: October 27, 2026 · 6 min read · By the Grey Peptides Editorial Board

Glass vials arranged in a laboratory rack
Photo by Jess Loiterton on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • On the headline numbers, retatrutide leads: 25.0% weight loss at 80 weeks in TRIUMPH-1, against 20.9% for tirzepatide in SURMOUNT-1 and 20.4% for CagriSema in REDEFINE 1, each counting everyone randomized.
  • Those trials differ in length, population and placebo response, so the gaps are indicative, not exact. The only direct comparisons so far put tirzepatide ahead of semaglutide and, by Novo Nordisk's February 2026 report, ahead of CagriSema, which failed to show non-inferiority.
  • Only tirzepatide is approved. As of October 27, 2026, CagriSema has been with the FDA since December 2025 without a decision we could find, and Lilly plans to file retatrutide in the first quarter of 2027.

Three ways to hit the same target

All three drugs build on GLP-1, the gut hormone behind semaglutide, and add something different. Tirzepatide High is one molecule that acts on both the GIP and GLP-1 receptors. CagriSema High is two molecules injected together: semaglutide for GLP-1 and cagrilintide, an amylin analogue, for the separate amylin satiety signal. Retatrutide Medium is one molecule that acts on three receptors, GIP, GLP-1 and glucagon; its discovery paper reports more GIP receptor activity than glucagon or GLP-1 receptor activity in the laboratory, and in obese mice glucagon-receptor-driven increases in energy expenditure added to the weight loss 1.

The scorecard, trial by trial

Each row is the drug's main phase 3 obesity trial or its head-to-head, at the highest dose (SURMOUNT-5 at each person's maximum tolerated dose), with the estimand the published paper uses for its primary result. As of October 27, 2026:

TrialWhoLengthDrug (top dose)PlaceboEstimand
TRIUMPH-1, retatrutide 12 mg2,339 adults, obesity, no diabetes80 weeks-25.0%-3.9%Treatment-regimen (everyone randomized)
REDEFINE 1, CagriSema 2.4/2.4 mg3,417 adults, obesity or overweight, no diabetes68 weeks-20.4%-3.0%Treatment-policy (everyone randomized)
SURMOUNT-1, tirzepatide 15 mg2,539 adults, obesity or overweight, no diabetes72 weeks-20.9%-3.1%Treatment-regimen (everyone randomized)
TRIUMPH-2, retatrutide 12 mg1,152 adults, BMI 27 or more, type 2 diabetes80 weeks-18.8%-5.1%Treatment-regimen (everyone randomized)
REDEFINE 2, CagriSema 2.4/2.4 mg1,206 adults, BMI 27 or more, type 2 diabetes68 weeks-13.7%-3.4%Treatment-policy
SURMOUNT-2, tirzepatide 15 mg938 adults, BMI 27 or more, type 2 diabetes72 weeks-14.7%-3.2%Treatment-regimen (everyone randomized)
SURMOUNT-5, tirzepatide (10 or 15 mg) vs semaglutide (1.7 or 2.4 mg)751 adults, obesity, no diabetes72 weeks-20.2% (tirzepatide)-13.7% (semaglutide)Head-to-head, open label

The sources: TRIUMPH-1 2, REDEFINE 1 3, SURMOUNT-1 4, TRIUMPH-2 5, REDEFINE 2 6, SURMOUNT-2 7 and SURMOUNT-5 8.

Why the numbers are not a straight race

The estimand matters more than most headlines admit. TRIUMPH-1's paper reports -25.0% at 12 mg under a treatment-regimen (intention-to-treat) estimand, counting everyone who was randomized 2; Lilly's topline release of May 21, 2026 led with 28.3% under its "efficacy estimand" and gave the 25.0% treatment-regimen figure beside it 9. CagriSema has the same split: 20.4% under the treatment-policy estimand 3, and 22.7% under the trial product estimand, which Novo Nordisk defines as the effect "if all participants adhered to treatment" 10. Compare like with like, and the counting-everyone figures in the table are the fair basis.

The trials also ran for different lengths, 68 to 80 weeks, so their end points are not taken at the same time. Placebo groups lost 3.0% to 3.9%, so the drug-minus-placebo gaps are about 21 points for retatrutide, about 18 points for tirzepatide and about 17 points for CagriSema. In the trials in people with type 2 diabetes, each drug produced less weight loss than in its trial without diabetes, and the order across these separate trials is the same: retatrutide, then tirzepatide, then CagriSema 5 7 6.

Direct comparisons are what settle questions like these, and there are few. SURMOUNT-5 found tirzepatide ahead of semaglutide, 20.2% against 13.7% at 72 weeks 8. On February 23, 2026 Novo Nordisk reported that REDEFINE 4, an 84-week head-to-head trial, did not show CagriSema non-inferior to tirzepatide 15 mg: 20.2% against 23.6% weight loss under the treatment-regimen estimand, and 23.0% against 25.5% had everyone adhered 11. No trial comparing retatrutide head-to-head with either drug has published.

Side effects and stopping

All three cause the same kind of side effects, mostly in the gut. In SURMOUNT-1, adverse events led 6.2% of people on tirzepatide 15 mg to stop, against 2.6% on placebo 4. In REDEFINE 1, gastrointestinal events affected 79.6% of those on CagriSema against 39.9% on placebo, mostly transient and mild to moderate 3. In TRIUMPH-2, diarrhoea affected 27% to 34% on retatrutide against 13%, and nausea 14% to 28% against 8%; stopping for adverse events or death was 12% on 9 mg and 8% on 12 mg against 5% on placebo 5. In TRIUMPH-1 the most common adverse events were gastrointestinal 2, and Lilly's topline release put stopping for adverse events at 11.3% on 12 mg against 4.9% on placebo 9. Lilly's topline release for TRIUMPH-4, a trial in knee osteoarthritis, put it at 18.2% on 12 mg against 4.0% on placebo, and said the rates were highly correlated with baseline BMI (12.1% on 12 mg in people with a BMI of 35 or more) 12.

Where each stands (as of October 27, 2026)

Tirzepatide is approved in the US as Mounjaro for type 2 diabetes (May 2022) and Zepbound for weight management (November 2023) 13. CagriSema was filed with the FDA in December 2025, which Novo Nordisk announced on December 18 14; FDA's list of 2026 novel drug approvals, current as of October 20, 2026, does not include it 15. Retatrutide is not approved anywhere; Lilly said on July 23, 2026 that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027 16. A filing starts a review; it does not set an approval date.

Until then, the only one of the three a doctor can prescribe in the US is tirzepatide. Neither retatrutide nor CagriSema has an approved product anywhere, so anything sold online under those names is an unapproved product no regulator has reviewed; our guide to the gray-market code names covers those listings.

Frequently asked questions

Is retatrutide better than tirzepatide?

In its phase 3 trial retatrutide produced more weight loss: 25.0% at 80 weeks against 20.9% at 72 weeks for tirzepatide in SURMOUNT-1, both counting everyone randomized. The trials were separate, and no head-to-head trial has published.

Is CagriSema better than Zepbound?

Not on the evidence so far. REDEFINE 1 found 20.4% weight loss at 68 weeks against 20.9% for tirzepatide 15 mg in SURMOUNT-1, and in Novo Nordisk's February 2026 head-to-head trial, REDEFINE 4, CagriSema did not show non-inferiority to tirzepatide (20.2% against 23.6% at 84 weeks).

Why do retatrutide figures differ between 25% and 28%?

They use different estimands. The published TRIUMPH-1 paper reports 25.0% at 12 mg under the treatment-regimen estimand, counting everyone randomized; Lilly's topline figure of 28.3% is its efficacy estimand.

When will retatrutide and CagriSema be available?

As of October 27, 2026, neither is approved. CagriSema has been under FDA review since December 2025, and Lilly plans to file retatrutide in the first quarter of 2027.

Sources

  1. Coskun, T., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab, 34(9), 1234-1247.e9. PMID: 35985340
  2. Jastreboff, A. M., et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med, . PMID: 42814954 · doi:10.1056/NEJMoa2604169
  3. Garvey, W. T., et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 393(7), 635-647. PMID: 40544433 · doi:10.1056/NEJMoa2502081
  4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med, 387(3), 205-216. PMID: 35658024 · doi:10.1056/NEJMoa2206038
  5. Bellido, V., et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet, . PMID: 42810372
  6. Davies, M. J., et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med, 393(7), 648-659. PMID: 40544432
  7. Garvey, W. T., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 402(10402), 613-626. PMID: 37385275
  8. Aronne, L. J., et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med, 393(1), 26-36. PMID: 40353578 · doi:10.1056/NEJMoa2416394
  9. Eli Lilly and Company (May 21, 2026). Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal TRIUMPH-1 trial. News release: 12 mg -28.3% (efficacy estimand) and -25.0% (treatment-regimen estimand) at 80 weeks; discontinuation due to adverse events 11.3% on 12 mg vs 4.9% placebo. Read October 27, 2026; cited without a link: we name manufacturers but do not link to them.
  10. Novo Nordisk (June 22, 2025). CagriSema 2.4 mg/2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine. Company announcement: 22.7% vs 2.3% at 68 weeks under the trial product estimand ("if all patients adhered to treatment"); 20.4% vs 3.0% under the treatment policy estimand. Read October 27, 2026; cited without a link.
  11. Novo Nordisk A/S (February 23, 2026). Company announcement on REDEFINE 4, furnished to the US SEC on Form 6-K: the 84-week trial "did not achieve its primary endpoint of demonstrating non-inferiority on weight loss" versus tirzepatide 15 mg; 20.2% vs 23.6% (treatment-regimen estimand), 23.0% vs 25.5% (efficacy estimand). Read on SEC EDGAR October 27, 2026; cited without a link.
  12. Eli Lilly and Company (December 11, 2025). TRIUMPH-4 topline results (retatrutide in obesity with knee osteoarthritis). News release: discontinuation due to adverse events 12.2% (9 mg), 18.2% (12 mg), 4.0% (placebo), "highly correlated with baseline BMI"; 8.8%, 12.1% and 4.8% in participants with BMI of 35 or more. Read October 27, 2026; cited without a link.
  13. Grey Peptides dataset, tirzepatide record (Drugs@FDA approvals of Mounjaro, May 2022, and Zepbound, November 2023); read October 27, 2026.
  14. Novo Nordisk (December 18, 2025). Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. News release. Cited without a link: we name manufacturers but do not link to them.
  15. US Food and Drug Administration. Novel Drug Approvals for 2026 (content current as of October 20, 2026); read October 27, 2026: no cagrilintide or CagriSema approval listed. FDA
  16. Eli Lilly and Company (July 23, 2026). Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. News release: Lilly plans to submit a Biologics License Application for retatrutide to FDA in Q1 2027. Cited without a link: we name manufacturers but do not link to them.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead